In a move to bolster its rare disease business, Ipsen has agreed to acquire Clementia Pharmaceuticals for up to US$1.3 B. Ipsen will gain access to Clementia’s lead Phase III candidate, palovarotene which, following an US FDA submission for the treatment of fibrodysplasia ossificans progressive (FOP) in the second half of 2019, is forecast to launch in 2020. A Phase III registrational trial evaluating a chronic dosing regimen for FOP, a Phase II trial for multiple osteochondromas, and a Phase I trial for dry eye disease are also ongoing.